- Home
- NVT vs MRNA Comparison
NVT vs MRNA Comparison
Compare NVT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- MRNA
- Stock Information
- Founded
- NVT 1903
- MRNA 2010
- Country
- NVT United Kingdom
- MRNA United States
- Employees
- NVT N/A
- MRNA N/A
- Industry
- NVT Industrial Machinery/Components
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVT Industrials
- MRNA Health Care
- Exchange
- NVT Nasdaq
- MRNA Nasdaq
- Market Cap
- NVT 18.1B
- MRNA 9.2B
- IPO Year
- NVT N/A
- MRNA 2018
- Fundamental
- Price
- NVT $111.64
- MRNA $27.08
- Analyst Decision
- NVT Strong Buy
- MRNA Hold
- Analyst Count
- NVT 11
- MRNA 15
- Target Price
- NVT $103.45
- MRNA $36.69
- AVG Volume (30 Days)
- NVT 2.3M
- MRNA 12.1M
- Earning Date
- NVT 10-31-2025
- MRNA 11-06-2025
- Dividend Yield
- NVT 0.72%
- MRNA N/A
- EPS Growth
- NVT 6.36
- MRNA N/A
- EPS
- NVT 3.64
- MRNA N/A
- Revenue
- NVT $3,578,600,000.00
- MRNA $2,232,000,000.00
- Revenue This Year
- NVT $27.44
- MRNA N/A
- Revenue Next Year
- NVT $12.69
- MRNA $10.38
- P/E Ratio
- NVT $30.64
- MRNA N/A
- Revenue Growth
- NVT 21.54
- MRNA N/A
- 52 Week Low
- NVT $41.71
- MRNA $23.04
- 52 Week High
- NVT $117.52
- MRNA $48.92
- Technical
- Relative Strength Index (RSI)
- NVT 61.57
- MRNA 55.06
- Support Level
- NVT $109.51
- MRNA $23.04
- Resistance Level
- NVT $114.15
- MRNA $25.56
- Average True Range (ATR)
- NVT 3.58
- MRNA 1.58
- MACD
- NVT 0.16
- MRNA 0.07
- Stochastic Oscillator
- NVT 64.71
- MRNA 65.26
About NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.